Clinical trial NCT00987064: Clinical Effects of Temperature Controlled Laminar Airflow (TLA)
Official title: Clinical Effects of Purified Air Administered to the Breathing Zone in Allergic Asthma
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Asthma
Perennial Allergy
Keywords: Protexo
Asthma
Temperature controlled Laminar Airflow
Perennial allergy
Quality of life
MiniAQLQ
FeNO
FEV1
PEF
Lead sponsor: Airsonett AB
Sponsor class: INDUSTRY
Collaborators: name: Karolinska University Hospital
name: University Hospital, Linkoeping
name: Quintiles, Inc.
First posted: 2009-09-30
Enrollment: 28
Sex: ALL
Minimum age (years): 12
Maximum age (years): 28
Standard ages: CHILD
ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to determine whether clean air administered to the breathing zone with Temperature controlled Laminar Airflow (TLA) during night is effective in the treatment of perennial allergic asthma.

Detailed description: Background: Exposure to inhaled allergens is a pathogenetic factor in allergic asthma. However, most studies that previously looked at air cleaning devices have shown little or no effect on patients with perennial allergic asthma. Aims and objectives: This study aims to investigate a novel treatment, TLA, using temperature controlled laminar airflow with a very low particle concentration directed to the breathing zone of teenagers and adults with allergic asthma during night sleep. The hypothesis is that the decreased allergen exposure during the night will have an effect on bronchial inflammation and quality of life. Method: Patients are randomized to start with active or placebo treatment for 10 weeks. All patients receive both active and placebo treatment with unfiltered air, with a 2-week wash-out period in between treatments. Maintenance treatment with inhaled corticosteroids is unaltered during the trial period. Health related quality of life (miniAQLQ)is the primary effectiveness measure. Exhaled nitric oxide (FeNO) and spirometry are also investigated.

Eligibility criteria: Inclusion Criteria:

* Diagnosed for asthma for more than 1 year.
* More than 12% reactivity in FEV1 on bronchodilating medication or less than 90% of the FEV1 reference value according to Hedenström.
* Perennial allergy
* At least 3-mm wheal reaction in a skin prick test to at least one of following: House dust, Mold spores, dust mites, animal hair and dander.
* Little or no reactivity to other inhalant allergens.
* No known allergy to another inhalant allergen or chemical to which there is exposure in winter time.
* No allergen injection treatment in the preceding 2 years.
* A history of a requirement for daily medication for asthma including;

  * 400µg steroid medication (Pulmicort or equal) for children and 800µg for adults.
  * Beta agonist treatment on less than 4 days per week.
* Willingness to follow the clinical trial protocol, including medications, baseline and follow-up visits and procedures.

Exclusion Criteria:

* Inclusion in another Allergen avoidance program.
* Smoking in the family
* Participation in a drug trial

Primary outcomes:
measure: Quality of life assessed by mini Asthma Quality of Life Questionnaire (miniAQLQ)
timeFrame: Every 2 weeks of the study period
Secondary outcomes:
measure: Airway inflammation measurement assessed by Exhaled nitric oxide (FeNO)
timeFrame: Every 5 week of the study period
measure: Lung function (FeV1, PEF)
timeFrame: Every 5 week of the study period
Other outcomes:
Locations:
city: Linkoeping
country: Sweden
facility: University Hospital, Linkoeping
city: Stockholm
country: Sweden
facility: Karolinska University Hospital
Study officials:
affiliation: Karolinska University Hospital
name: Christophe Pedroletti, MD, PhD.
role: PRINCIPAL_INVESTIGATOR
References:
citation: Pedroletti C, Millinger E, Dahlen B, Soderman P, Zetterstrom O. Clinical effects of purified air administered to the breathing zone in allergic asthma: A double-blind randomized cross-over trial. Respir Med. 2009 Sep;103(9):1313-9. doi: 10.1016/j.rmed.2009.03.020. Epub 2009 May 13.